(131)I-ch81C6

human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma, in phase I trial (6/2006)

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        (131)I-ch81C6: 1
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        (131)I-ch81C6: 1
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        (131)I-ch81C6: 1

Experts

1.	Akabani, Gamal: 1 article (06/2006)
2.	Badruddoja, Michael A: 1 article (06/2006)
3.	Bigner, Darell D: 1 article (06/2006)
4.	Coleman, R Edward: 1 article (06/2006)
5.	Desjardins, Annick: 1 article (06/2006)
6.	Dowell, Jeannette M: 1 article (06/2006)
7.	Friedman, Allan H: 1 article (06/2006)
8.	Friedman, Henry S: 1 article (06/2006)
9.	Gururangan, Sridharan: 1 article (06/2006)
10.	Herndon, James E: 1 article (06/2006)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2006 - "We treated 47 patients with (131)I-ch81C6 doses up to 4.44 GBq (120 mCi), including 35 with newly diagnosed tumors (strata A and B) and 12 with recurrent disease (stratum C). "
2.	Glioma (Gliomas) 06/01/2006 - "Our objective was to determine the effect of these differences on the maximum tolerated dose (MTD), pharmacokinetics, dosimetry, and antitumor activity of (131)I-ch81C6 administered into the surgically created resection cavity (SCRC) of malignant glioma patients. "